re: Ann: Patrys to Initiate Clinical Trial wi... This is all just speculation, but we know Amgen paid over $10 billion for Onyx, largely on the strength of their one MM drug.
PAB has maybe 520 million shares issued? (Correct me if wrong.)
Even at $1 per share it's only valued at just over half a billion. With a deep pipeline, good patent protection and low toxicity I would have thought it should be valued at more than that (in the long term).
Anyone agree/disagree?
Fat Harry's Cat
re: Ann: Patrys to Initiate Clinical Trial wi... This is all...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 24652453 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 25089307 | 16 |
View Market Depth
| Last trade - 16.12pm 11/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable